Keros Therapeutics to Present at the 28th Annual Congress of the European Hematology Association
May 11 2023 - 4:01PM
Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel treatments for patients suffering from
hematological, pulmonary and cardiovascular disorders with high
unmet medical need, today announced that three abstracts will be
presented from the KER-050 and ALK2 hematology programs at the 28th
Annual Congress of the European Hematology Association (“EHA”), to
be held both virtually and in person from June 8 through 15, 2023.
The following abstracts were posted to the EHA website on May
11, 2023, 10:00 a.m. Eastern time.
Clinical Presentation
“KER-050 treatment improved markers of erythropoietic
activity and hematopoiesis over six months which resulted in
hematological responses across a broad, lower-risk MDS
population”
- Abstract Code: S166
- Session Title: s417 MPN and MDS: Targeting red cells and
platelets
- Session Date and Time: June 9, 2023; 8:45 a.m. - 10:00 a.m.
Eastern time
Preclinical Presentations
“A modified activin receptor type II ligand trap
RKER-050 restored erythropoiesis in a mouse model of
myelofibrosis”
- Abstract Code: P992
- Session Title: Poster session
- Session Date and Time: June 9, 2023; 12:00 p.m. – 1:00 p.m.
Eastern time
“Combining ALK2 inhibition with a modified activin
receptor IIA ligand trap provided additive benefits in resolving
anemia in a mouse model of anemia of inflammation”
- Abstract Code: P1488
- Session Title: Poster session
- Session Date and Time: June 9, 2023; 12:00 p.m. – 1:00 p.m.
Eastern time
About KER-050
Keros’ lead protein therapeutic product candidate, KER-050, is
an engineered ligand trap comprised of a modified ligand-binding
domain of the transforming growth factor-beta receptor known as
activin receptor type IIA that is fused to the portion of the human
antibody known as the Fc domain. KER-050 is being developed for the
treatment of low blood cell counts, or cytopenias, including anemia
and thrombocytopenia, in patients with myelodysplastic syndromes
and in patients with myelofibrosis.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of novel
treatments for patients suffering from hematological, pulmonary and
cardiovascular disorders with high unmet medical need. Keros is a
leader in understanding the role of the transforming growth
factor-beta family of proteins, which are master regulators of red
blood cell and platelet production as well as of the growth, repair
and maintenance of a number of tissues, including blood vessels and
heart tissue. Keros’ lead protein therapeutic product candidate,
KER-050, is being developed for the treatment of low blood cell
counts, or cytopenias, including anemia and thrombocytopenia, in
patients with myelodysplastic syndromes and in patients with
myelofibrosis. Keros’ lead small molecule product candidate,
KER-047, is being developed for the treatment of functional iron
deficiency. Keros’ third product candidate, KER-012, is being
developed for the treatment of pulmonary arterial hypertension and
for the treatment of cardiovascular disorders.
Cautionary Note Regarding Forward-Looking
Statements
Statements contained in this press release regarding matters
that are not historical facts are “forward-looking statements”
within the meaning of the Private Securities Litigation Reform Act
of 1995, as amended. Words such as "anticipates," "believes,"
"expects," "intends," “plans,” “potential,” "projects,” “would” and
"future" or similar expressions are intended to identify
forward-looking statements. Examples of these forward-looking
statements include statements concerning: Keros’ presentation plans
for the upcoming EHA annual meeting. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. These risks and uncertainties include, among others:
Keros’ limited operating history and historical losses; Keros’
ability to raise additional funding to complete the development and
any commercialization of its product candidates; Keros’ dependence
on the success of its product candidates, KER-050, KER-047 and
KER-012; that Keros may be delayed in initiating, enrolling or
completing any clinical trials; competition from third parties that
are developing products for similar uses; Keros’ ability to obtain,
maintain and protect its intellectual property; and Keros’
dependence on third parties in connection with manufacturing,
clinical trials and pre-clinical studies.
These and other risks are described more fully in Keros’ filings
with the Securities and Exchange Commission (“SEC”), including the
“Risk Factors” section of the Company’s Quarterly Report on Form
10-Q, filed with the SEC on May 4, 2023, and its other documents
subsequently filed with or furnished to the SEC. All
forward-looking statements contained in this press release speak
only as of the date on which they were made. Except to the extent
required by law, Keros undertakes no obligation to update such
statements to reflect events that occur or circumstances that exist
after the date on which they were made.
Investor Contact:
Justin Frantzjfrantz@soleburytrout.com617-221-9100
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From Apr 2024 to May 2024
Keros Therapeutics (NASDAQ:KROS)
Historical Stock Chart
From May 2023 to May 2024